MIND Diet Plus Caloric Restriction No Better for Cognition
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 19, 2023 -- The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) with mild caloric restriction does not change cognition or brain magnetic resonance imaging (MRI) outcomes compared with a control diet with mild caloric restriction, according to a study published online July 18 in the New England Journal of Medicine to coincide with the annual Alzheimer's Association International Conference, held from July 16 to 20 in Amsterdam.
Lisa L. Barnes, Ph.D., from the Rush Alzheimer's Disease Center in Chicago, and colleagues performed a two-site randomized controlled trial involving older adults without cognitive impairment with a family history of dementia, a body mass index greater than 25 kg/m2, and a suboptimal diet to examine the cognitive effects of the MIND diet with mild caloric restriction compared with a control diet with mild caloric restriction (301 and 303 participants, respectively). To promote weight loss, all participants received counseling regarding adherence to their assigned diet plus support.
The researchers found that from baseline to year 3, both groups had improvements in global cognition scores, with increases of 0.205 and 0.170 standardized units in the MIND- and control-diet groups, respectively. The two groups had similar changes in white-matter hyperintensities, hippocampal volumes, and total gray- and white-matter volumes on MRI.
"Participants who followed the MIND diet had small improvements in a global measure of cognition that were similar to those who followed a control diet with mild caloric restriction," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Self-, Partner-Reported Cognitive Decline Linked to Tau
THURSDAY, May 30, 2024 -- Individuals who self-report and whose partners report cognitive decline have greater tau, which is driven by elevated beta-amyloid (Aβ), according...
Peanut Consumption Starting in Infancy Provides Lasting Tolerance
THURSDAY, May 30, 2024 -- Peanut consumption starting in infancy and continuing to age 5 years provides lasting tolerance into adolescence, according to a study published in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.